Navigation Links
China Pharmaceutical Industry Examined in New Kelly Scientific Publications Report Available at MarketPublishers.com
Date:7/19/2013

London, UK (PRWEB) July 19, 2013

In 2011, China’s pharmaceutical market was evaluated at around USD 40 billion. Currently, the country ranks as the third largest pharmaceutical market in the world and is also recognized as the main hub for Asian markets. The market growth is fueled by the increasing prevalence of chronic diseases in China, with a total of more than 250 million cases as of today. The production of generic drugs and vaccines represent the key sectors of the Chinese pharmaceutical market.

China’s pharmaceutical market is predicted to experience skyrocketing growth in the coming years, and will reach a value of approximately USD 200 billion by 2020. Diabetic drug annual sales are expected to exceed USD 2 billion in 2019. The Chinese oncology sector is likely to go beyond USD 2.19 billion by 2017.

New research report “Pharmaceutical Industry China Q2 2013 - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” worked out by Kelly Scientific Publications has been recently published by Market Publishers Ltd.

Report Details:

Title: Pharmaceutical Industry China Q2 2013 - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges
Published: July, 2013
Pages: 142
Price:    US$ 2,600.00
http://marketpublishers.com/report/life_sciences/pharmaceuticals/pharmaceutical-industry-china-q2-2013-an-in-depth-analysis-of-multinational-n-chinese-biopharma-companies-industry-trends-environment-regulation.html

The report provides a comprehensive guide to the Chinese pharmaceuticals market. It characterizes the country’s business environment, discloses critical data on the industry’s performance, traces prevailing industry trends and presents an all-round market assessment by therapeutic area. The study contains a SWOT analysis, an examination of the regulative landscape, and insights into the Chinese pharmaceutical export market. The report delves into the competitive landscape and grants access to the detailed profiles of the foreign and domestic companies operating in the market. Discussions of the important industry issues along with forecast projections and future growth rates are available in the research study.

Report Scope:

  •     Chronic disease prevalence statistics for China.
  •     Accurate description of the country’s business environment.
  •     In-depth analysis of the Chinese pharmaceutical market.
  •     Comprehensive market assessment by product type.
  •     Details on the regulative landscape and novel drug developments.
  •     Insights into China’s pharmaceutical export market.
  •     Profiles of the leading multinational and domestic companies operating in the country-market.
  •     Examination of the major factors driving and restraining the market growth.
  •     Identification of the main market challenges and opportunities.
  •     Discussion of the important industry issues.
  •     Chinese pharmaceutical market forecast through 2020.

More new research reports by the publisher can be found at Kelly Scientific Publications page.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10946310.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
2. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
5. 3SBio Inc. to Present at the UBS Greater China Conference 2012
6. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
7. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
8. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
9. Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region
10. China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR
11. China Biologic Has Announced the Resignation of CFO Y. Tristan Kuo and Named Mr. Ming Yang as Interim CFO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... CA (PRWEB) , ... May 05, 2016 , ... ... closed on a definitive agreement to acquire Algynomics, a research-stage pain diagnostics company. ... data to identify individuals at increased risk for the development of chronic pain, ...
(Date:5/5/2016)... ... 2016 , ... American Process, Inc. (API) announced that the ... 9,322,133 and 9,322,134, to API and its affiliated companies for BioPlus® nanocellulose technology. ... compositions. In addition to these patents and U.S. Patent No. 9,187,865 awarded ...
(Date:5/5/2016)... 2016  Why are two uber-successful former agency presidents ... launching a new venture—yet going about things in ... truly helping clients raise the value of their offerings ... different type of collaboration. The result is ... and medical device sectors. Elevate specializes in shaping and ...
(Date:5/5/2016)... ... May 05, 2016 , ... ProMIS Neurosciences ... its first three targets, it has identified a fourth in a series of ... the development and progression of Alzheimer’s disease (AD). , “This discovery ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):